Orion S.A. (OEC) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Orion S.A. (OEC) stock forecast summary
Our AI ranks Orion S.A. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Orion S.A. is a small-cap company with a market capitalization of $326M. It ranks number 6 by market capitalization among the 9 Miscellaneous Chemical Products issuers in our coverage with a current forecast. Its Gross Margin of 18.4% is the lowest of the 9 peers that report one. Its D/E Ratio of 4.22x is the highest of the 8 peers that report one.
A per-ticker accuracy statistic for OEC is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, OEC included.
Follow OEC freeOEC price chart and AI forecast
How OEC ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Orion S.A. (OEC) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Miscellaneous Chemical Products peers listed below that report each metric.
Valuation & Market
| Metric | OEC | Rank |
|---|---|---|
| Market Cap | $326M | 6/9 |
| P/B Ratio | 0.86x | 7/8 |
| Dividend Yield | 1.41% | – |
| EPS | $-1.37 | – |
| Book Value/Share | $6.73 | – |
| Revenue/Share | $32.25 | – |
| FCF/Share | $0.45 | – |
Profitability & Margins
| Metric | OEC | Rank |
|---|---|---|
| ROE | -25.3% | 6/7 |
| ROA | -4.8% | 5/8 |
| ROIC | -0.2% | 7/9 |
| Gross Margin | 18.4% | 9/9 |
| Operating Margin | -0.2% | 6/9 |
| Net Margin | -5.3% | 5/8 |
| EBT Margin | -3.5% | 6/9 |
| Tax Rate | -50.7% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | OEC | Rank |
|---|---|---|
| Current Ratio | 1.03x | 7/9 |
| Quick Ratio | 0.64x | 7/9 |
| D/E Ratio | 4.22x | 1/8 |
| Financial Leverage | 5.22x | 1/8 |
| Interest Coverage | 0.3x | 5/8 |
| Working Capital | $18M | 7/9 |
Cash Flow
| Metric | OEC | Rank |
|---|---|---|
| Operating Cash Flow | $177M | 3/9 |
| Free Cash Flow | $26M | 4/5 |
| Capital Spending | -$151M | 4/5 |
| OCF Growth YoY | 50.0% | 2/7 |
| FCF/Sales | 1.4% | 4/5 |
| CapEx/Sales | 8.3% | 1/5 |
Operational Efficiency
| Metric | OEC | Rank |
|---|---|---|
| Asset Turnover | 0.92x | 4/7 |
| Receivables Turnover | 6.1x | 3/5 |
| Inventory Turnover | 5.4x | 3/9 |
| Fixed Assets Turnover | 1.7x | 6/7 |
| Days Sales Outstanding | 60 days | 3/5 |
| Days Inventory | 68 days | 7/9 |
| Payables Period | 53 days | 6/9 |
| Cash Conversion Cycle | 74 days | 4/5 |
Income Statement
| Metric | OEC | Rank |
|---|---|---|
| Total Revenue | $1.82B | 3/7 |
| Operating Income | -$3M | 7/9 |
| Net Income | -$96M | 8/8 |
| R&D Expense | $29M | 3/8 |
| SG&A Expense | $236M | 3/7 |
| Cost of Goods Sold | $1.49B | 3/9 |
Dividend & Shareholder Information
| Metric | OEC | Rank |
|---|---|---|
| Dividends Per Share | $0.08 | – |
| Shares Outstanding | 57M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $734M | 36.9% of assets |
| Cash & Short-term Investments | $51M | 2.6% of assets |
| Accounts Receivable | $300M | 15.1% of assets |
| Inventory | $276M | 13.9% of assets |
| Total Liabilities | $1.61B | 80.9% of assets |
| Short-term Debt | $498M | 25.0% of assets |
OEC quarterly financials and insider trading
Orion S.A. (OEC) industry peers
Companies classified under the same SEC industry code as Orion S.A. (Miscellaneous Chemical Products): 9 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| OEC Orion S.A. | ▲ | $326M |
| ESI Element Solutions Inc | ▶ | $9.06B |
| CBT Cabot Corp | ▼ | $3.90B |
| WDFC Wd 40 Co | ▶ | $2.74B |
| FTK Flotek Industries Inc/Cn/ | ▲ | $980M |
| ASPI Asp Isotopes Inc. | ▼ | $350M |
| ARQ Arq, Inc. | ▲ | $86M |
| FSI Flexible Solutions International Inc | ▶ | $78M |
| PURE Pure Bioscience, Inc. | ▲ | $10M |
Where OEC sits on the market map
Orion S.A. (OEC) stock news
Loading...
Orion S.A. (OEC) stock forecast FAQ
What is the Orion S.A. (OEC) stock forecast?
Our AI ranks Orion S.A. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Orion S.A. stock predictions?
A per-ticker accuracy statistic for OEC is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Orion S.A. forecasts updated?
Orion S.A. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Orion S.A.'s industry peers?
9 issuers in our coverage, OEC included, share the SEC industry code Miscellaneous Chemical Products. The largest are: Element Solutions Inc (ESI), Cabot Corp (CBT), Wd 40 Co (WDFC), Flotek Industries Inc/Cn/ (FTK), Asp Isotopes Inc. (ASPI), Arq, Inc. (ARQ).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.